Wall Street brokerages expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to post earnings per share of ($0.23) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with estimates ranging from ($0.25) to ($0.21). AcelRx Pharmaceuticals reported earnings of ($0.20) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 15%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 1st.
According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full-year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.79). For the next year, analysts forecast that the business will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.84) to ($0.47). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.85 million.
A number of institutional investors have recently made changes to their positions in ACRX. BlackRock Inc. boosted its holdings in AcelRx Pharmaceuticals by 196.6% in the fourth quarter. BlackRock Inc. now owns 2,331,736 shares of the specialty pharmaceutical company’s stock worth $5,386,000 after acquiring an additional 1,545,702 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of AcelRx Pharmaceuticals by 55.1% during the fourth quarter. Bank of New York Mellon Corp now owns 67,149 shares of the specialty pharmaceutical company’s stock worth $155,000 after purchasing an additional 23,866 shares during the period. Raymond James & Associates lifted its holdings in shares of AcelRx Pharmaceuticals by 96.7% during the fourth quarter. Raymond James & Associates now owns 29,500 shares of the specialty pharmaceutical company’s stock worth $68,000 after purchasing an additional 14,500 shares during the period. Northern Trust Corp lifted its holdings in shares of AcelRx Pharmaceuticals by 15.4% during the fourth quarter. Northern Trust Corp now owns 132,197 shares of the specialty pharmaceutical company’s stock worth $305,000 after purchasing an additional 17,672 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of AcelRx Pharmaceuticals by 38.2% during the fourth quarter. Geode Capital Management LLC now owns 478,349 shares of the specialty pharmaceutical company’s stock worth $1,104,000 after purchasing an additional 132,252 shares during the period. Institutional investors own 15.52% of the company’s stock.
Shares of NASDAQ:ACRX traded down $0.06 during midday trading on Thursday, hitting $2.78. The stock had a trading volume of 70,895 shares, compared to its average volume of 1,728,354. The stock has a 50-day moving average price of $2.46. The company has a market capitalization of $224.89 million, a P/E ratio of -3.42 and a beta of 2.24. The company has a quick ratio of 4.91, a current ratio of 5.03 and a debt-to-equity ratio of 0.79. AcelRx Pharmaceuticals has a fifty-two week low of $1.99 and a fifty-two week high of $5.05.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Featured Article: Why do companies issue convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.